A: We’ve been doing our best since day one, and we believe we’re making good on every promise we’ve made to our subscribers.
For example, on our very first day of publication, we alerted our subscribers to a biotech stock called Galapagos NV based on a recommendation from one of our experts.
Since then the stock has climbed as high as 213%, proving that we do deliver on such promises as:
- Providing “Access” to Our Experts: Private Briefing readers learned of the Galapagos profit opportunity because one of our financial editors had recommended it to the subscribers of his high-dollar trading service.
- Making Sure That You “Profit While You Learn:” Galapagos shares rose 103.5% in a bit more than six months after we recommended the shares to Private Briefing subscribers. From the outset, with updates along the way, we demonstrated to subscribers how to use big trends (such as those in the biotech sector) to identify major profit opportunities.
- Providing “Ahead-of-the-Curve Investment Advice and Recommendations: Months after we recommended Galapagos – and after it had run up as much as 103.5% (it moved much higher later) – institutional investors began taking big positions in Galapagos’ stock. And one of those institutions was Baker Bros. – a private equity player based on Madison Ave., that’s well-known for its biotech/healthcare savvy. In all, Baker Bros. purchased 6.48% of Galapagos’ outstanding shares.
- Generating Big Winners: In our first three years of publication, we’ve had 33 recommendations double or better, including a biotech stock that gained 629%. We’ve also had 11 recommendations end up as takeover or merger plays.